Gallbladder Adenocarcinoma With Squamous Metaplasia Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0046854 (Gallbladder Adenocarcinoma With Squamous Metaplasia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093222Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaTreatment